Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus.

Trial Profile

Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2015

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms RETAIN
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jan 2015 According to the ClinicalTrials.gov record, status changed from suspended to discontinued.
    • 14 Jan 2015 According to the ClinicalTrials.gov record, status changed from suspended to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top